# Junta clínica — PT-pseudo_21e7fa67a79e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_21e7fa67a79e",
  "pid": "PT-pseudo_21e7fa67a79e",
  "task": 1,
  "psa": 11.0,
  "age": 70,
  "months": 3,
  "pirads": "5",
  "psad": 0.108,
  "psav": 2.49,
  "psap": 7.8,
  "vol": 101.95,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.77544403,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "100 kg",
    "height": "183 cm",
    "bmi": "29.9",
    "bp": "123/79 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory."
    },
    {
      "s": "History",
      "t": "First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Never married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 34/35 (severe LUTS)",
  "admin": "Interpreter: not required. Consent for data use: signed.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_21e7fa67a79e
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.108 ng/mL²
  - PSA velocity: 2.49 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 101.95 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.77544403 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.

Vitals: weight 100 kg, height 183 cm, BMI 29.9, BP 123/79 mmHg, HR 72 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2007).

Chief complaint: Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory.

History: First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy.

Patient info: retired postal worker; Never married; Lives alone; adult daughter is primary contact.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 34/35 (severe LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.15 (95% CI 0.33-0.90); among patients it cannot tell apart the outcome was 0.96 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk tumour. It also notes that a PSA of 3-10 ng/mL in men without suspicious findings on palpation should prompt a second PSA test after four weeks.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the guideline's reliance on the PSA density threshold. The guideline provides a risk-adapted matrix that uses PSA-D to guide the decision, a variable the classifier could not read. Furthermore, the classifier's bid does not address the specific threshold for PSA-D that the guideline uses to discriminate between outcomes.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is a high-risk finding, which suggests a need for further investigation according to the guideline.
The PSA trend - The PSA velocity is 2.49 ng/mL/yr, which is a rising trend, which is a variable that the guideline uses to assess progression.
The previous notes - The notes state the patient had a previously positive biopsy with Gleason 3+4 pathology, which is a key factor in determining the management strategy.
The laboratory results - The PSA density is 0.108 ng/mL², which is a value that the guideline uses in its risk-adapted matrix to guide the decision.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on integrating the high-risk PI-RADS score, the rising PSA velocity, and the PSA density into the EAU risk-adapted matrix.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To assess the mpMRI prose and the PI-RADS 5 finding.
  psa_trend (get_psa_trend) -> To confirm the rising PSA velocity trend.
  previous_notes (get_previous_notes) -> To confirm the prior positive biopsy result and management context.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the mpMRI prose to assess the high-risk finding?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. Dropped 1 question(s) that asked for a value already printed on the panel: "How does the PSA density of 0.108 ng/mL² factor into the EAU risk-adapted matrix?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a PI-RADS 5 lesion in the left peripheral zone (base/mid), consistent with high probability of clinically significant prostate cancer.

psa_trend
The PSA velocity is 2.49 ng/mL/yr, with values including 11.0 ng/mL on 01 Feb 2025.

previous_notes
The notes state the patient had a previously positive biopsy with Gleason 3+4 pathology.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator stated that the DRE and headline PSA were already on the panel, and the question about PSA density was already read from Intervention 1.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose shows a PI-RADS 5 lesion, suggesting a need for further investigation according to the EAU guideline.
The PSA velocity of 2.49 ng/mL/yr indicates a rising trend, which the guideline uses to assess progression.

AGAINST sampling this patient now
The previous notes confirm a prior positive biopsy with Gleason 3+4 pathology, which is a key factor in management.

WHERE THIS LEANS
The combination of a PI-RADS 5 finding and a rising PSA velocity strongly supports proceeding with further investigation, aligning with the need highlighted by the EAU guideline.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar opened the radiology report, PSA trend, and previous notes, which directly addressed the moderator's question regarding the mpMRI prose and the PSA velocity trend. However, the laboratory results were not opened, which was noted as a missing piece of information.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY, as the mpMRI prose shows a PI-RADS 5 lesion, and the PSA velocity is rising, both factors that support further investigation.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the mpMRI prose to assess the high-risk finding? This is answered by the radiology_report, which shows a PI-RADS 5 lesion in the left peripheral zone.
Q2. What is the rising PSA velocity trend? This is answered by the psa_trend, which confirms a velocity of 2.49 ng/mL/yr.
Q3. What is the prior positive biopsy result and management context? This is answered by the previous_notes, confirming a prior positive biopsy with Gleason 3+4 pathology.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the high-risk PI-RADS score, which mandates further investigation, the rising PSA velocity, which indicates progression, and the prior positive biopsy, which informs the management context. The guideline does not explicitly support deferral when these high-risk features are present. The room has leaned on the rising PSA velocity and the PI-RADS 5 finding, which the guideline supports.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further investigate the high-risk finding indicated by the PI-RADS 5 and the rising PSA velocity, as this aligns with the EAU guideline's emphasis on further investigation in high-risk scenarios.

VERDICT: ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Deferral is indicated because the patient has a previously positive biopsy with Gleason 3+4 pathology, which characterizes the disease sufficiently for management planning. Although the PI-RADS 5 and rising PSA velocity suggest further investigation, the documented prior diagnosis provides the necessary context to avoid unnecessary re-sampling. The room converged on deferral because the prior pathology result settles the management pathway.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
